Impact of bowel movement condition on immune checkpoint inhibitor efficacy in patients with advanced non-small cell lung cancer.

Yuki KatayamaTadaaki YamadaKeiko TanimuraAkihiro Yoshimura Takayuki TakedaYusuke ChiharaNobuyo TamiyaYoshiko KanekoJunji UchinoKoichi Takayama

Published in: Thoracic cancer (2019)

Stool abnormality might be a predictive biomarker for the clinical benefit of ICI treatment in patients with NSCLC. Further investigations are warranted to validate our findings.

Keyphrases

advanced non small cell lung cancer
epidermal growth factor receptor
small cell lung cancer
tyrosine kinase
replacement therapy